BioSenic SA

BIOS

BE0974280126

Pharmaceuticals

Real-time Euronext Bruxelles Other stock markets 05:53:34 2024-04-25 am EDT			5-day change	1st Jan Change
0.0176 ^EUR	+10.00%		-13.73%	-71.24%

Apr. 11	Biosenic: launch of a debt restructuring plan	CF
Mar. 12	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

Bone Therapeutics Sa Reports Earnings Results for the Half Year Ended June 30, 2021

September 08, 2021 at 03:15 am EDT

Bone Therapeutics SA announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 773,000 compared to EUR 732,000 a year ago. Operating loss was EUR 5.721 million compared to EUR 7.381 million a year ago. Net loss was EUR 6.072 million compared to EUR 9.830 million a year ago.

Latest news about BioSenic SA

Biosenic: launch of a debt restructuring plan	Apr. 11	CF
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	Mar. 12	CI
BioSenic Raises Capital to Fund US FDA Application for Oral Arsenic Trioxide	Feb. 05	MT
BioSenic S.A. announced that it has received ?0.5 million in funding from Société Boursier.com SA, Gestys Sprl, Friedland Gestion	Feb. 01	CI
BioSenic Unit Wins Canadian Patent for Therapeutic Platform	Jan. 30	MT
BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform	Jan. 30	CI
BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress	Jan. 25	CI
BioSenic Files US Patent for Osteoarthritis Therapy	Jan. 23	MT
BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA	Jan. 23	CI
Biosenic: partnership with Phebra PTY evolves	Jan. 15	CF
BioSenic Signs Binding Term Sheet with Phebra for Oral Formulation Development of cGvHD Treatment	Jan. 15	MT
BioSenic Reaches Agreement on A Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment	Jan. 15	CI
BioSenic Names Chief Scientific Officer as COO	Jan. 10	MT
Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer	Jan. 10	CI
BioSenic S.A. announced that it expects to receive ?1.2 million in funding from Abo-Security S.R.L.	Jan. 07	CI
BioSenic S.A. announced that it expects to receive $9.6 million in funding	Dec. 05	CI
BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD	23-09-27	CI
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis	23-09-19	CI
BioSenic Strikes Debt Restructuring Deal with Creditors; Stock Gains	23-09-14	MT
BioSenic Secures Patent in China for Arsenic Trioxide Platform	23-08-24	MT
BioSenic Commences Debt Renegotiation, Secures Standstill Agreement	23-07-10	MT
Global markets live: Airbus, Intel, Meta Platforms, Berkshire Hathaway...	23-06-19
BioSenic Halts Mid-stage Bone Repair Study to Focus on Autoimmune Disease Asset	23-06-19	MT
BioSenic S.A. Puts Phase IIb Allob Trial on Hold	23-06-19	CI
BioSenic to Advance Viscosupplement Plans for Knee Osteoarthritis	23-05-17	MT

Chart BioSenic SA

Duration

Period

More charts

Company Profile

BioSenic SA is a leading biotech company specializing in the development of clinical assets issued from the allogeneic cell therapy platform ALLOB and from the Arsenic TriOxide (ATO) platform. Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures. Following the merger in October 2022, BioSenic SA combines the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger also enables Biosenic SA to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO.

Sector

Pharmaceuticals

Calendar

01:00am - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.016 EUR

Average target price

0.1 EUR

Spread / Average Target

+525.00%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOSENIC SA	-71.24%	3.14M
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+23.25%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+12.51%	219B
ROCHE HOLDING AG	-9.78%	196B
NOVARTIS AG	+6.65%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

BioSenic SA

Equities

BIOS

BE0974280126

Pharmaceuticals

Bone Therapeutics Sa Reports Earnings Results for the Half Year Ended June 30, 2021

Latest news about BioSenic SA

Chart BioSenic SA

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals